Scholar Rock Holding (SRRK) Stock Overview
A biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SRRK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Scholar Rock Holding Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$44.78 |
| 52 Week High | US$49.82 |
| 52 Week Low | US$22.71 |
| Beta | 0.75 |
| 1 Month Change | -5.96% |
| 3 Month Change | -0.60% |
| 1 Year Change | 29.80% |
| 3 Year Change | 335.18% |
| 5 Year Change | -32.57% |
| Change since IPO | 188.90% |
Recent News & Updates
Recent updates
Muscle-Targeted SMA Therapies And Global Expansion Will Reshape Long-Term Outlook
Catalysts About Scholar Rock Holding Scholar Rock Holding focuses on developing muscle-targeted therapies for rare and severe neuromuscular diseases, led by its apitegromab program for spinal muscular atrophy and a broader anti myostatin pipeline. What are the underlying business or industry changes driving this perspective?Scholar Rock: Apitegromab's Path Forward Remains Intact, Maintaining Buy Rating
Jan 06Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade
Apr 17Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Jan 30Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High
Dec 24Scholar Rock: SMA Program Strides Forward With Positive Clinical Data
Oct 07Scholar Rock: Solid Data And Good Prospects
Jan 12Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy
Oct 20Jay Backstrom is the new CEO at Scholar Rock
Sep 20Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology
Jul 12Shareholder Returns
| SRRK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.1% | 1.5% | -0.6% |
| 1Y | 29.8% | 28.2% | 21.7% |
Return vs Industry: SRRK exceeded the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: SRRK exceeded the US Market which returned 21.3% over the past year.
Price Volatility
| SRRK volatility | |
|---|---|
| SRRK Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SRRK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SRRK's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 289 | David Hallal | www.scholarrock.com |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company’s novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors.
Scholar Rock Holding Corporation Fundamentals Summary
| SRRK fundamental statistics | |
|---|---|
| Market cap | US$5.08b |
| Earnings (TTM) | -US$377.94m |
| Revenue (TTM) | n/a |
Is SRRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRRK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$208.44m |
| Gross Profit | -US$208.44m |
| Other Expenses | US$169.50m |
| Earnings | -US$377.94m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 40.6% |
How did SRRK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/10 14:03 |
| End of Day Share Price | 2026/03/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Scholar Rock Holding Corporation is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Etzer Darout | Barclays |
| Evan Seigerman | BMO Capital Markets Equity Research |